Screening for autoimmune thyroid disorders after spontaneous abortion is cost-saving and it improves the subsequent pregnancy rate

• Published in: BMC pregnancy and childbirth 2013-11, Vol.13 (1), p.217-217, Article 217
• Main Authors: Bartáková, Jana, Potluková, Eliška, Rogalewicz, Vladimír, Fait, Tomáš, Schöndorfová, Dita, Telička, Zdeněk, Krátký, Jan, Jiskra, Jan
• Format: Article
• Language: English
• Subjects: Abortion, Spontaneous - etiology; Adult; Autoantibodies - blood; Autoimmune Diseases - complications; Autoimmune Diseases - diagnosis; Autoimmune Diseases - drug therapy; Cost analysis; Cost-Benefit Analysis; Cross-Sectional Studies; Drug dosages; Female; Follow-Up Studies; Gynecology; Hospitals; Humans; Hypothyroidism; Hypothyroidism - complications; Hypothyroidism - diagnosis; Hypothyroidism - drug therapy; Infertility; Infertility, Female - etiology; Iodide Peroxidase - immunology; Iodine; Laboratories; Mass Screening - economics; Miscarriage; Obstetrics; Physiology; Pregnancy; Pregnancy Rate; Reproductive health; Thyroid diseases; Thyrotropin - blood; Thyroxine - blood; Thyroxine - economics; Thyroxine - therapeutic use; Ultrasonic imaging; Womens health
• ISSN: 1471-2393; 1471-2393
• DOI: 10.1186/1471-2393-13-217

Hypothyroidism and/or autoimmune thyroid disorders (AITD) may contribute to spontaneous abortions (SpA). Cost-effectiveness analyses of thyroid screening in women after SpA are lacking. Our aim was to evaluate the cost-effectiveness of screening for AITD and/or hypothyroidism and their treatment in women after SpA with regard to their reproductive health. We performed a cross-sectional non-randomized study with follow-up in 2008-2011 in the settings of Departments of Endocrinology and Obstetrics/Gynecology of a university hospital. We enrolled 258 women after SpA before the 12th gestational week and followed them for a median of 3 years. At enrollment, serum concentrations of thyroid stimulatory hormone (TSH), antibodies to thyroid peroxidase (TPOAb) and free thyroxine (FT4) were measured and thyroid ultrasound performed. Women with overt hypothyroidism were treated with levothyroxine (n = 45; 61.6%) and women with subclinical hypothyroidism or euthyroid AITD were treated (n = 28; 38.4%) or left untreated (n = 38; 14.7%). Euthyroid women without signs of AITD served as controls (n = 147; 57.0%). Of the 38 untreated women with AITD and/or subclinical hypothyroidism, 8 (21.1%) reported secondary infertility as compared to 16/147 (10.9%) controls and 3/73 (4.1%) treated women (p = 0.021). Treatment was associated with an increased rate of successfully completed subsequent pregnancies (increment of 6 newborns/100 women) and a savings of €19,539/100 women. Total costs per successfully completed pregnancy were €1,189 in controls, €1,564 in the treated, and €2,488 in the untreated women. Screening for thyroid disorders in women after SpA and treatment with levothyroxine is cost-saving and it improves the subsequent pregnancy rate.